NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
0.4615
+0.0425 (10.14%)
Apr 25, 2025, 4:00 PM EDT - Market closed

Company Description

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer.

The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures.

The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NextCure, Inc.
NextCure logo
Country United States
Founded 2015
IPO Date May 9, 2019
Industry Biotechnology
Sector Healthcare
Employees 43
CEO Michael Richman

Contact Details

Address:
9000 Virginia Manor Road, Suite 200
Beltsville, Maryland 20705
United States
Phone 240 399 4900
Website nextcure.com

Stock Details

Ticker Symbol NXTC
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001661059
CUSIP Number 65343E108
ISIN Number US65343E1082
Employer ID 47-5231247
SIC Code 2834

Key Executives

Name Position
Michael S. Richman MSBA Co-Founder, Chief Executive Officer, President and Director
Dr. Solomon Langermann Ph.D. Chief Scientific Officer
Dr. Lieping Chen M.D., Ph.D. Co-Founder and Chairman of Scientific Advisory Board
Steven P. Cobourn CPA Chief Financial Officer
Dr. Timothy Mayer Ph.D. Chief Operating Officer
Kevin G. Shaw Senior Vice President and General Counsel
Sourav Kundu Ph.D. Senior Vice President of Development and Manufacturing
Dr. Sebastien Maloveste Ph.D. Senior Vice President of Business Development
Dr. Udayan Guha M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Apr 25, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025 DEF 14A Other definitive proxy statements
Apr 15, 2025 PRE 14A Other preliminary proxy statements
Apr 10, 2025 8-K Current Report
Mar 6, 2025 10-K Annual Report
Mar 6, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A Filing
Feb 3, 2025 8-K Current Report
Jan 10, 2025 8-K Current Report
Dec 10, 2024 8-K Current Report